PRLD Stock Analysis
PR
Uncovered
Prelude Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Prelude Therapeutics, Inc. operates as a cancer drug discovery company. The company is headquartered in Wilmington, Delaware and currently employs 122 full-time employees. The company went IPO on 2020-09-25. The Company’s product candidate pipeline includes PRT543, PRT811, PRT1419, PRT2527, PRT-SCA2 and PRT3645. PRT543 is in a Phase I clinical trial in advanced solid tumors and select myeloid malignancies. PRT811 is a being studied in a Phase I clinical trial in unselected patients with solid tumors, including high-grade glioma. PRT1419 is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1. PRT2527 is designed to be a potent and selective Cyclin-dependent kinase 9 (CDK9), inhibitor. The Company’s drug discovery engine is designed to identify biological targets and create new chemical entities (NCEs). Its pipeline includes six programs, including methyltransferases, kinases, protein-protein interactions and targeted protein degraders.